One result of the Oncology explosion over the past 10 years has been the advent of CAR T therapy. In fact, we have seen two recent approvals, both for hematological cancers. Yet, the industry has not made nearly as much progress in solid tumors. Kineticos’ Operating Executive, Steve Buckanavage, recently caught up with Dr. Jeffrey Skolnik, VP of Clinical Development at Inovio Pharmaceuticals to discuss the notion of CAR T succeeding in both solid and liquid tumors.
- Part 1 explores how targeted combination therapies and our new understanding of the biological basis of disease has significantly improved patient outcomes.
- Part 2 discusses what the next inflection point in CAR-T is.
Subscribe to Kineticos to receive weekly emails containing insightful content.